Gasdermin E (GSDME)
Overview
Gasdermin E (GSDME), also known as DFNA5, is a pore-forming protein in the gasdermin family that is best known for its role in regulated cell death. In many biological contexts, GSDME is cleaved by caspase-3 (caspase-3), releasing an N-terminal fragment that can disrupt the plasma membrane and drive pyroptosis, a lytic and highly inflammatory form of cell death. This places GSDME at the intersection of apoptosis and pyroptosis, where it can convert a caspase-3–mediated apoptotic signal into membrane rupture, cytokine release, and immunogenic cell death.
Because of this switch-like function, GSDME has attracted substantial interest in cancer biology and therapeutic development. In tumor settings, activation of the caspase-3/GSDME axis has been explored as a way to overcome apoptosis resistance and promote antitumor immunity. Recent studies have linked GSDME-dependent pyroptosis with enhanced release of proinflammatory cytokines, increased antigen presentation, and improved immune-cell recruitment, including CD8+ T cells, often in combination with checkpoint inhibitor strategies such as anti-PD-1/PD-L1 or anti-CTLA-4 therapy.
Recent Publications Summary
Recent publications have continued to position Gasdermin E (GSDME) as a key executioner of pyroptosis in cancer and inflammatory disease models, often downstream of caspase-3 activation. In non-small cell lung cancer, Cauloside A was reported to interact with Toll-like receptor 4 (TLR4) and induce JNK phosphorylation followed by caspase-3/GSDME-dependent pyroptosis, with GSDME cleavage occurring independently of GSDMD 42085840May. Similarly, mitochondria-targeted zwitterionic nanogels were designed to accumulate in mitochondria and, upon laser irradiation, amplify reactive oxygen species to activate the caspase-3/GSDME pyroptosis pathway, producing strong tumor inhibition in vivo 42143709May. Saquinavir was also shown to trigger caspase-3-GSDME-dependent pyroptosis in hepatocellular carcinoma, in part by disrupting glucose metabolism, increasing reactive oxygen species, targeting OTUD5, and promoting JAK1 degradation and mitochondrial damage 41687749Feb.
Several studies linked GSDME-mediated pyroptosis to immunogenic antitumor effects and combination strategies. A manganese vacancy-engineered Prussian blue derivative was reported to generate reactive oxygen species under second near-infrared irradiation, causing GSDME-mediated tumor cell pyroptosis and subsequent mitochondrial DNA release that cooperated with Mn2+ to activate the cGAS-STING pathway and enhance antitumor immunity 42251536Jun. In a related nanomedicine approach, a composite nanovesicle co-delivering β-lapachone, Mn2+, and decitabine was designed to amplify reactive oxygen species, induce mitochondrial damage, promote cytosolic mtDNA release, and activate cGAS-STING signaling; intrinsic apoptosis in this system also led to caspase-3 cleavage of GSDME and pyroptosis 41871782Mar. In anti-PD-1-refractory tumors, pan-PKC inhibition was found to overcome resistance by inducing caspase-3/GSDME-dependent immunogenic pyroptotic cell death, alongside tumor-intrinsic PD-L1 degradation and enhanced CD8+ T cell recruitment and effector function 42234523Jun.
Beyond oncology, GSDME was implicated in sepsis-associated cognitive dysfunction. In a cecal ligation and puncture model, GSDME expression and cleavage were increased in hippocampal astrocytes, and astrocyte-specific GSDME knockdown alleviated cognitive impairment, supporting a pathogenic role for GSDME-mediated pyroptosis in sepsis-associated encephalopathy 42055495Apr. Geniposide, identified as an active component of a traditional Chinese medicine formulation, was reported to inhibit GSDME activation and prevent translocation of cleaved GSDME to the cell membrane, improving sepsis-induced cognitive dysfunction in vivo 42055495Apr.
GSDME has also been highlighted in studies of mitotic stress and cell-death switching. Dual inhibition of TRIP13 and Aurora A in Rb-deficient cancer cells induced prolonged mitotic arrest, DNA damage, and concurrent apoptotic and GSDME-mediated pyroptotic cell death 42013305Apr. More broadly, recent review articles emphasized the caspase-3/GSDME axis as a central molecular switch in the apoptosis-to-pyroptosis transition and discussed its relevance for overcoming apoptosis resistance and reshaping tumor immunity 41490685Jan41655514Feb.
What Changes, What Holds
1. GSDME remains a broadly reused executioner of caspase-3-linked pyroptosis across additional tumor contexts
REINFORCES These studies do not displace the settled model that GSDME is cleaved downstream of caspase-3 to drive lytic death; they extend that same mechanism into new drug and nanomaterial settings. The added value is practical rather than conceptual: they strengthen the view that GSDME can be therapeutically engaged in lung cancer and hepatocellular carcinoma to amplify tumor killing, including through ROS-linked mitochondrial injury 42085840May41687749Feb.
2. GSDME-driven pyroptosis can be harnessed to couple tumor killing with cGAS-STING activation and checkpoint sensitization
REINFORCES This work sharpens, rather than revises, the Overview’s claim that GSDME-dependent pyroptosis can enhance antitumor immunity and support checkpoint strategies. What changes is the mechanistic packaging: pyroptotic membrane rupture is being linked more explicitly to mtDNA release, innate immune sensing, and improved CD8+ T-cell responses, including in anti-PD-1-refractory disease 42251536Jun42234523Jun. The baseline already anticipated this immunogenic direction.
3. GSDME is now implicated in sepsis-associated cognitive injury, not just cancer biology
NEW DIRECTION These findings extend GSDME into a disease area the Overview does not cover: astrocyte-associated pyroptosis in sepsis-related encephalopathy. That leaves the established apoptosis-to-pyroptosis switch intact, but adds a pathogenic role in the brain and suggests that blocking GSDME activation or membrane translocation may be neuroprotective in sepsis 42055495Apr. The new evidence is preclinical and needs confirmation in broader models.
4. GSDME can participate in mitotic-stress cell death programs, but this does not overturn its caspase-3-centered role
REINFORCES Dual TRIP13/Aurora A inhibition adds another route into the same death machinery: prolonged mitotic arrest and DNA damage converge on apoptotic and GSDME-mediated pyroptotic death. That broadens the contexts in which GSDME can be engaged, yet it still fits the established account of GSDME as a downstream executor that converts upstream stress into membrane rupture 42013305Apr. The review articles simply restate and consolidate that model 41490685Jan41655514Feb.
Overview update candidates: sepsis-associated cognitive dysfunction as a new GSDME-linked disease role; GSDME involvement in mitotic-stress cell death programs.
gasdermin e
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding gasdermin e are described as follows:
- pyroptosis (Biological Process) — 3 papers: PMIDs 42143709, 42138395, 41490685
- reactive oxygen species (Chemical) — 2 papers: PMIDs 41871782, 41687749
- chemodynamic therapy (Therapy) — 1 paper: PMIDs 41871782
- endoplasmic reticulum (Cellular Component) — 1 paper: PMIDs 42138395
- gasdermin (Protein) — 1 paper: PMIDs 41655514
- glycolytic process (Biological Process) — 1 paper: PMIDs 41687749
- hepatocellular carcinoma (Disease) — 1 paper: PMIDs 41687749
- inflammasome complex (Cellular Component) — 1 paper: PMIDs 41490685
- Malignant Disease (Disease) — 1 paper: PMIDs 41490685
- non-small-cell lung carcinoma (Disease) — 1 paper: PMIDs 41655514
- PDCD-1 (Protein) — 1 paper: PMIDs 41655514
- Programmed Death-Ligand 1 (Protein) — 1 paper: PMIDs 41655514
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study gasdermin e:
- 4T1 tumor model (Organism) — 1 paper: PMIDs 41871782
- anti-CTLA-4 (Therapy) — 1 paper: PMIDs 42234523
- anti-PD-1/PD-L1 (Therapy) — 1 paper: PMIDs 42234523
- caspase-3 (Protein) — 1 paper: PMIDs 41871782
- composite nanovesicle (PLMD) (Technology) — 1 paper: PMIDs 41871782
- copper-doped manganese vacancy-engineered Prussian blue derivative (Other) — 1 paper: PMIDs 42251536
- decitabine (Chemical) — 1 paper: PMIDs 41871782
- ER800-FA-NPs (Technology) — 1 paper: PMIDs 42138395
- flow cytometric techniques (Technology) — 1 paper: PMIDs 42138395
- Immunofluorescence (Technology) — 1 paper: PMIDs 42138395
- manganese ions (Chemical) — 1 paper: PMIDs 41871782
- N-acetyl-β-neuraminic acid (Chemical) — 1 paper: PMIDs 41871782
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to gasdermin e include:
- Death executioner caspase related to Apopain/Yama Dmel_CG14902 (Protein) — 4 papers: PMIDs 42143709, 41687749, 41655514, 41490685
- Gasdermin D (Protein) — 2 papers: PMIDs 41655514, 41490685
- C-C motif chemokine receptor 5 (Protein) — 1 paper: PMIDs 42234523
- carbon tetrachloride (Chemical) — 1 paper: PMIDs 42234523
- CASP1 (Protein) — 1 paper: PMIDs 41655514
- CASP8 (Protein) — 1 paper: PMIDs 41490685
- caspase triggers (Other) — 1 paper: PMIDs 41655514
- caspase-3 (Protein) — 1 paper: PMIDs 42234523
- cGAS-STING pathway (Pathway) — 1 paper: PMIDs 41871782
- epigenetic modulators (Other) — 1 paper: PMIDs 41655514
- ER800 (Chemical) — 1 paper: PMIDs 42138395
- FOSL2 (Gene) — 1 paper: PMIDs 41490685
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with gasdermin e include:
- CD8+ S100B+ T cells (Cellular Component) — 2 papers: PMIDs 42251536, 42234523
- 99.3% tumor inhibition (Clinical Metric) — 1 paper: PMIDs 42143709
- antitumor efficacy (Clinical Metric) — 1 paper: PMIDs 42138395
- ATF6 (Protein) — 1 paper: PMIDs 42138395
- caspase-3 (Protein) — 1 paper: PMIDs 42138395
- caspase-3/GSDME pathway-mediated pyroptosis (Other) — 1 paper: PMIDs 42138395
- CD4+CD25+ regulatory T cells (Cellular Component) — 1 paper: PMIDs 42234523
- CD8+ T cell recruitment and effector function (Biological Process) — 1 paper: PMIDs 42234523
- cGAS-STING activation (Other) — 1 paper: PMIDs 41871782
- complete primary tumor regression (Clinical Metric) — 1 paper: PMIDs 42251536
- dendritic cell (Cellular Component) — 1 paper: PMIDs 42251536
- dendritic cell maturation (Biological Process) — 1 paper: PMIDs 41871782
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding gasdermin e are summarized below:
- anti-malarial drug resistance (Other) — 1 paper: PMIDs 41490685
- checkpoint inhibitor (Therapy) — 1 paper: PMIDs 41490685
- epigenetic reprogramming (Other) — 1 paper: PMIDs 41871782
- ER-targeted pyroptosis (Other) — 1 paper: PMIDs 42138395
- ICB-refractory cancers (Disease) — 1 paper: PMIDs 42234523
- Immune Resistance (Biological Process) — 1 paper: PMIDs 42234523
- photopyroptosis (Biological Process) — 1 paper: PMIDs 42143709
- precision cancer therapy (Therapy) — 1 paper: PMIDs 42143709
- pyroptosis (Biological Process) — 1 paper: PMIDs 41687749
- salvage strategy (Other) — 1 paper: PMIDs 42234523
- therapeutic targets (Other) — 1 paper: PMIDs 41490685
- tumor imaging-guided therapy (Other) — 1 paper: PMIDs 42138395